In summary, our study herein demonstrated that the CCF-mediated PTT, NR2F6 gene silencing, and aPD-L1 combination treatment generated an attractive concept in HCC therapy that could stimulate effective synergistic therapeutic immunotherapy to inhibit tumor growth. Here, PITX1 is linked to neoplasm.